<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862145</url>
  </required_header>
  <id_info>
    <org_study_id>MRX34-102</org_study_id>
    <nct_id>NCT02862145</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions</brief_title>
  <acronym>MRX34-102</acronym>
  <official_title>A Multicenter Phase 1B Pharmacodynamics Study of MRX34, MicroRNA miR-Rx34 Liposomal Injection, in Patients With Advanced Melanoma and Biopsy Accessible Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirna Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirna Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the biomarkers, pharmacodynamics and pharmacokinetics
      of the liposomal micro-ribonucleic acid-34 (microRNA-34, miR-34). Melanoma patients with
      easily accessible lesions will undergo serial biopsies and serial blood samples will be
      collected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MRX34 Induction Therapy consists of 3 cycles of MRX34 treatment given over an approximately 8
      week period. Dexamethasone 10 mg PO (or IV) will be given as premedication. On Days 1-5 of
      each treatment cycle, MRX34 will be given as a daily infusion followed by 16 days of rest. At
      screening a tumor biopsy sample will be required from all patients. Additional biopsies will
      be collected at Cycle 1 Day 3 and the end of Cycles 1 and 3 (Day 18 +/- 1 day)
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    5 immune related serious adverse events in Phase 1 study
  </why_stopped>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak blood concentration and Area Under the Curve (AUC) of MRX34 after IV dosing and drug concentration in tissue biopsies</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events associated with MRX34 treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in tumor measurements over time using RECIST criteria.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>RNA sequencing analysis of PBMCs to evaluate gene expression through TLR signaling, RIG-I Pathway and PD1/PD-L1 Blockade.</measure>
    <time_frame>During 3 months of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of MRX34 accumulation in tumor tissue measured by qPCR and CISH.</measure>
    <time_frame>During 3 months of treatment</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment with MRX34</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Injection of MRX34 for 5 days followed by 16 days rest with premedication of dexamethasone daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRX34</intervention_name>
    <description>Treatment of melanoma with pharmacodynamics biopsy of tissue and blood</description>
    <arm_group_label>Treatment with MRX34</arm_group_label>
    <other_name>miR-Rx34</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Premedication during the week of treatment</description>
    <arm_group_label>Treatment with MRX34</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years of age

          -  Advanced or metastatic cutaneous, acral or mucosal melanoma

          -  Tumor lesions accessible to serial biopsies

          -  ECOG ≤ 1

          -  ANC ≥, Plts ≥100,000 /mm3

        Exclusion Criteria:

          -  Serious active non-malignant disease

          -  Central Nervous System metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Smith, MSN</last_name>
    <role>Study Director</role>
    <affiliation>Mirna Therapeutics</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biosy accessible melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

